Profile
Alan Tyndall is the founder of Magenta Therapeutics, Inc. (2015).
He is currently a Professor-Emeritus at the University of Basel (since 1991) and serves as Secretary at the World Scleroderma Foundation.
Mr. Tyndall received his undergraduate degree from the University of Sydney in 1972.
Mr. Tyndall is also the founder of Iterata AG.
Alan Tyndall active positions
| Companies | Position | Start |
|---|---|---|
| University of Basel | Corporate Officer/Principal | 1990-12-31 |
| World Scleroderma Foundation | Corporate Secretary | - |
| Iterata AG | Founder | - |
Former positions of Alan Tyndall
| Companies | Position | End |
|---|---|---|
| MAGENTA THERAPEUTICS | Founder | - |
Training of Alan Tyndall
| The University of Sydney | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
| World Scleroderma Foundation | |
| Iterata AG |
- Stock Market
- Insiders
- Alan Tyndall
